NCT03868592 Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis
| NCT ID | NCT03868592 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Obesity, Morbid |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2019-08-01 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2019-08-01 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to answer these questions.
Eligibility Criteria
Inclusion Criteria: * BMI 40 - 50 kg/m2. * Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery Exclusion Criteria: * Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg/dL * Active coronary artery disease * Participation in structured exercise (\>2 times per week for 30 minutes or longer) * Smoking * Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids) * Renal insufficiency (serum creatinine \> 1.5mg/dl) * Chronic active liver disease (Bilirubin \> 17mmol/L, AST \> 144 IU/L, or ALT\>165IU/L) * Pregnancy or breastfeeding.
Contact & Investigator
Michael D Jensen, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT03868592 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Obesity, Morbid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03868592 currently recruiting?
Yes, NCT03868592 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.
Where is the NCT03868592 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT03868592 clinical trial?
NCT03868592 is sponsored by Mayo Clinic. The principal investigator is Michael D Jensen, MD at Mayo Clinic. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.